This is the authors' abstract. We don't add key points for this paper.
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death and current therapeutic strategies are often unsatisfactory. Identification and development of more efficacious therapies is urgently needed. Immunotherapy offered encouraging results in preclinical models during the last decades, and several clinical trials have explored its therapeutic application in PDAC. The aim of this review is to summarize the results of clinical trials conducted to evaluate the future perspective of immunotherapy in the treatment of PDAC.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Paniccia et al. (2015) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: